Question:

How does the Moderator Decide which postings are appropriate to Post on the Purdue Cytometry Mail List?

by  |  earlier

0 LIKES UnLike

Re: FACSCalibur vs. XL & Naming babies -Reply

From: Mark Edinger (edin...@cesmtp.ccf.org)

Date: Mon Dec 18 1995 - 15:46:28 EST

• Next message: George Babcock: "anti-GM-CSF receptor antibody"

• Previous message: T. Vincent Shankey: "Re: Activated platelets"

• Messages sorted by: [ date ] [ thread ] [ subject ]

>>> Mike Salmon <salm...@rheuma.bham.ac.uk> - 12/18/95 5:29 AM >>>

Matbe it was just recieving about 50 messages in one go that did it,

but I think that about 25% were in the latter catagory and too many

in the former. A bit of fun is nice but I think the list is

beginning to get a bit over-trivial. That said I find the somewhat

acrimonious and rather pointless disputes about energy transfer

semantics even worse. This dispute has nothing to do with the

relative merits of the two instruments and everything to do with

peoples egos. Couldn't you conduct it by Email?

Mike

Mike Salmon

Department of Rheumatology

The Medical School

University of Birmingham

Birmingham B15 2TT

United Kingdom

Tel: 44 (0)121 414 6780

Fax: 44 (0)121 414 6794

Mike,

I completely agree with you. After all, the only person worse

than a fool is the person who argues with one.

Mark

• Next message: George Babcock: "anti-GM-CSF receptor antibody"

• Previous message: T. Vincent Shankey: "Re: Activated platelets"

______________________________________...

This archive was generated by hypermail 2.1.6 : Thu Jan 01 2004 -

17:30:40 EST

 Tags:

   Report

1 ANSWERS


  1. looks like advertising is verboten and is going to be cracked down on hard very soon.

    beyond that, I would guess if it doesn&#039;t settle back down to scientific discussions only very soon after that, all the extra cruft and meta-discussions will be verboten too.

Question Stats

Latest activity: earlier.
This question has 1 answers.

BECOME A GUIDE

Share your knowledge and help people by answering questions.